Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    D00456

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,364Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alto Neuroscience Secures Patent for ALTO-207 in Depression
    Alto Neuroscience Secures Patent for ALTO-207 in Depression

    14 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260114749833/en/Alto-Neuroscience-Strengthens-Intellectual-Property-Portfolio-with-Issuance-of-New-Method-of-Treatment-Patent-for-ALTO-207-in-Depression

    BUSINESSWIRE
    14 Jan 2026
    Share Share
    Shilpa Medicare Seeks US Approval for 5-HT3 Antagonist in CINV
    Shilpa Medicare Seeks US Approval for 5-HT3 Antagonist in CINV

    12 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-12/shilpa-medicare-targets-us-approval-of-5-ht3-receptor-antiemetic-for-chemotherapy-induced-nausea-and-vomiting-cinv

    PHARMIWEB
    12 Jan 2026
    Share Share
    Shilpa Medicare Aims For US Approval Of Chemo Nausea Drug
    Shilpa Medicare Aims For US Approval Of Chemo Nausea Drug

    09 Jan 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/shilpa-medicare-aims-for-us-approval-of-chemo-nausea-drug-18815

    INDPHARMAPOST
    09 Jan 2026
    Share Share
    Enforcement Report - Week of January 7, 2026
    Enforcement Report - Week of January 7, 2026

    07 Jan 2026

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-7-2026-42601.pdf

    FDA
    07 Jan 2026
    Share Share
    RedHill Advances RHB-102 for GLP-1 GI Side Effects
    RedHill Advances RHB-102 for GLP-1 GI Side Effects

    05 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhills-rhb-102-progresses-in-multiple-gi-indications-including-glp-1-therapy-related-gi-side-effects-302652577.html

    PR NEWSWIRE
    05 Jan 2026
    Share Share
    Enforcement Report - Week of December 24, 2025
    Enforcement Report - Week of December 24, 2025

    24 Dec 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-24-2025-58363.pdf

    FDA
    24 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.